Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

Biopharma deal activity in October totaled $22.31 billion, marking a 72% jump from $13.01 billion in September. Year-to-date deal values have decreased by 2%, from $175.29 billion during the first 10 ...

As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D ...

Gender bias in cardiac treatment guidelines is putting women at risk because guidelines are written based on clinical trials conducted mostly in men. As previously reported in BioWorld, nearly 70% of ...

The first filing to emerge from Identifyher Ltd. seeks to gain protection for a wearable sensor that women can wear daily to track potential symptoms of perimenopause, providing them with data that ...

Keymed Biosciences Co. Ltd. is out-licensing global rights, excluding China, for its bispecific antibody, CM-336, to Platina Medicines Ltd. in a deal worth up to $626 million plus sales royalties.

With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in a potential $745 ...

Syndax Pharmaceuticals Inc. won U.S. FDA approval – the company’s second this year – for menin inhibitor Revuforj (revumenib) with a black box warning for differentiation syndrome. “We’ve long ...

Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...

Trogenix Ltd. has emerged from stealth with a focus on treating cancer through viral immunotherapy. The company was founded as a spinout from the University of Edinburgh last year.

Cancer Targeted Technology LLC has been awarded the phase I portion ($400,000) of a fast track phase I/II ($2.4 million) Small Business Innovation Research (SBIR) grant by the National Cancer ...

Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.